Human pharmacokinetics of WR-2721
- 1 August 1986
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 12 (8) , 1501-1504
- https://doi.org/10.1016/0360-3016(86)90203-8
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Hydrolysis of S-2-(3-aminopropylamino)ethylphosphorothioate (WR-2721)Biochemical Pharmacology, 1986
- Measurement of S-2-(3-Aminopropylamino)ethanethiol (WR1065) in Blood and TissuesJournal of Liquid Chromatography, 1986
- Treatment of Hypercalcemia in Parathyroid Cancer with WR-2721,5-2(3aminopropylamino) Ethyl-Phosphorothioic AcidAnnals of Internal Medicine, 1985
- Measurement of WR-2721, WR-1065, and WR-33278 in plasmaInternational Journal of Radiation Oncology*Biology*Physics, 1985
- A Liquid Chromatographic Electrochemical Assay for S-2-(3-Aminopropylamino) Ethylphosphorothioate (WR2721) in Human PlasmaJournal of Liquid Chromatography, 1984
- Phase I trials of WR-2721 and cis-platinumInternational Journal of Radiation Oncology*Biology*Physics, 1984
- Phase I Controlled trials of WR-2721 and cyclophosphamideInternational Journal of Radiation Oncology*Biology*Physics, 1984
- Toxicity of WR-2721 administered in single and multiple dosesInternational Journal of Radiation Oncology*Biology*Physics, 1984
- Dephosphorylation of WR-2721 with mouse tissue homogenatesInternational Journal of Radiation Oncology*Biology*Physics, 1984
- Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721International Journal of Radiation Oncology*Biology*Physics, 1984